Filter by
Format
All
Sort by
Newest

Inflammation

  • Nintedanib
/ph/inflammation/nintedanib/ssc-ild/data-ra-ild-inbuild-trial-subgroup

3:58
A1-R101||A2-R101||Data on RA-ILD from INBUILD Trial (Subgroup)
/ph/inflammation/nintedanib/ssc-ild/ild-risk-factors-ra-patients

4:02
A1-R101||A2-R101||ILD Risk Factors in RA Patients
/ph/inflammation/nintedanib/ssc-ild/managing-ctd-ild-patients

1:48
A1-R101||A2-R101||Managing CTD ILD Patients
/ph/inflammation/nintedanib/ssc-ild/initiating-treatment-ssc-ild

3:48
A1-R101||A2-R101||Initiating Treatment for SSc-ILD
/ph/inflammation/nintedanib/ipf/irreplaceable-tomorrow-jpn-video-gp

4:43
FSIN||Irreplaceable Tomorrow JPN video: GP
/ph/inflammation/nintedanib/ssc-ild/irreplaceable-tomorrow-video-rheuma

2:50
FSIN||Irreplaceable Tomorrow video: Rheuma
/ph/inflammation/nintedanib/efficacy/progressive-pulmonary-fibrosis-ppf-diagnosis-and-treatment-atsersjrsalat-guideline

Progressive Pulmonary Fibrosis (PPF) - Diagnosis and Treatment in the ATS/ERS/JRS/ALAT Guideline (Infographics)
/ph/inflammation/nintedanib/expert-view/side-effect-management-adherence-panel-discussion-dr-nicole-goh-ms-charlotte-ild-nurse

28:54
Side effect management & adherence (Panel discussion) - by Dr Nicole Goh, Ms Charlotte (ILD Nurse), Dr Felix, Dr Voon
/ph/inflammation/nintedanib/expert-view/recent-developments-management-ild-dr-felix-chua-royal-brompton-hospital

24:23

Recent developments in the management of ILD - Dr Felix Chua (Royal Brompton Hospital)
/ph/inflammation/nintedanib/about-pulmonary-fibrosis/how-recognize-ild-ppf-patients-ctd

How to recognize ILD in PPF patients with CTD
/ph/inflammation/nintedanib/ipf/ipf-acute-exacerbations-brochure

IPF Acute Exacerbations Brochure
/ph/inflammation/nintedanib/ipf/recognize-pulmonary-fibrosis-hrct-scans

Recognize Pulmonary Fibrosis on HRCT Scans
/ph/inflammation/nintedanib/ssc-ild/time-essence-suspect-fibrotic-interstitial-lung-disease

Time is of the essence: Suspect fibrotic interstitial lung disease
/ph/inflammation/nintedanib/ipf/ipf_urgency_to_treat_infographic

IPF Urgency to Treat Infographic
/ph/inflammation/nintedanib/expert-videos/pccp-midyear-convention-lecture-progressive-pulmonary-fibrosis

41:55

PCCP Midyear Convention Lecture - Progressive Pulmonary Fibrosis
/ph/inflammation/nintedanib/expert-videos/expert-video-ild-management

1:32
A2-R101||Experts Video on ILD Management
/ph/inflammation/nintedanib/expert-videos/rheum-mte-management-strategies-key-highlights-dr-oliver-distler

A2-R101||Rheum MTE – Management Strategies Key highlights - Dr. Oliver Distler
/ph/inflammation/nintedanib/expert-videos/rheum-mte-management-strategies-key-highlights-dr-anna-maria-hoffmann-vold

A2-R101||Rheum MTE – Management Strategies Key highlights - Dr. Anna Maria Hoffmann-Vold
/ph/inflammation/nintedanib/expert-videos/rheum-mte-management-strategies-key-highlights-dr-m-aringer

A2-R101||Rheum MTE – Management Strategies Key highlights - Dr. M. Aringer
/ph/inflammation/nintedanib/expert-videos/rheum-mte-management-strategies-key-highlights-dr-v-smith

A2-R101||Rheum MTE – Management Strategies Key highlights - Dr. V.Smith
/ph/inflammation/nintedanib/expert-videos/ra-ild-patient-profile-julie

A1-R101||A2-R101||RA-ILD Patient Profile - Julie
/ph/inflammation/nintedanib/expert-videos/ssc-ild-patient-profile-stephanie

A1-R101||A2-R101||SSc-ILD Patient Profile - Stephanie
/ph/inflammation/nintedanib/expert-videos/ctd-ild-pathophysiology-moa

4:45
A1-R101||CTD-ILD Pathophysiology & MoA
/ph/inflammation/nintedanib/expert-videos/expert-videos-ssc-ild-management-chapter-5

2:39
A1-R101||A2-R101||Expert Videos on SSc-ILD Management - Chapter 5
/ph/inflammation/nintedanib/expert-videos/expert-videos-ssc-ild-management-chapter-2

4:03
A1-R101||A2-R101||Expert Videos on SSc-ILD Management - Chapter 2
/ph/inflammation/nintedanib/expert-videos/expert-videos-ssc-ild-management-chapter-1

4:21
A1-R101||A2-R101||Expert Videos on SSc-ILD Management - Chapter 1

Heart Failure

  • Empagliflozin
/ph/metabolic-hf/empagliflozin/experts-video/lets-talk-hhf

4:28
PTPHF||JRDHF||Let's Talk - HHF
/ph/metabolic-hf/empagliflozin/experts-video/lets-talk-efficacy-consistency-results-across-lvef

2:52
PTPHF||JRDHF||Let’s Talk – Efficacy - Consistency of results across LVEF
/ph/metabolic-hf/empagliflozin/experts-video/lets-talk-guidelines-hfref

4:25
PTPHF||JRDHF||Let's Talk - Guidelines HFrEF
/ph/metabolic-hf/empagliflozin/experts-video/lets-talk-impact-sglt2i-trials-hfpef

5:42
PTPHF||JRDHF||Let's Talk - Impact of SGLT2i trials in HFpEF
/ph/metabolic-hf/empagliflozin/experts-video/lets-talk-guidelines-evolution-hfpef

4:22
PTPHF||JRDHF||Let’s Talk – Guidelines Evolution for HFpEF
/ph/metabolic-hf/empagliflozin/experts-video/lets-talk-impact-early-benefits

2:27
PTPHF||JRDHF||Let's Talk - Impact of early benefits
/ph/metabolic-hf/empagliflozin/experts-video/lets-talk-sglt2i-ideal-therapy

3:53
PTPHF||JRDHF||Let's Talk - SGLT2i as ideal therapy
/ph/metabolic-hf/empagliflozin/experts-video/lets-talk-kidney-benefits

3:01
PTPHF||JRDHF||Let's Talk - Kidney benefits
/ph/metabolic/empagliflozin/experts-video/empagliflozins-proven-efficacy-and-safety-hf-patients-or-without-t2d

2:14
JRDHF||Empagliflozin's Proven Efficacy and safety in HF patients with or without T2D
/ph/metabolic/empagliflozin/experts-video/empagliflozins-robust-renal-data-full-spectrum-hf

1:47
JRDHF||Empagliflozin's robust renal data in the full spectrum of HF
/ph/metabolic/empagliflozin/experts-video/empagliflozin-has-consistent-cv-benefits-full-spectrum-hf

2:29
JRDHF||Empagliflozin has consistent CV benefits in the full spectrum of HF
/ph/metabolic/empagliflozin/experts-video/empagliflozin-jardiance-improves-qol-hf-patients

3:42
JRDHF||Empagliflozin JARDIANCE improves QoL of HF patients
/ph/metabolic/empagliflozin/experts-video/early-initiation-empagliflozin-full-spectrum-hf

3:23
JRDHF||Early initiation of Empagliflozin in the full spectrum of HF
/ph/metabolic/empagliflozin/experts-video/initiating-empagliflozin-hf-patients-low-egfr

2:09
JRDHF||Initiating Empagliflozin in HF patients with low eGFR
/ph/metabolic-hf/empagliflozin/jardiance-hf/jardiance-10-mfg-now-approved-full-spectrum-hf

Jardiance 10 mfg is now approved for the full spectrum of HF
/ph/metabolic-hf/empagliflozin/prescribing-information/empagliflozin-metformin-hci-jardiance-duo

Empagliflozin Metformin HCI (Jardiance Duo®) Prescribing Information
/ph/metabolic-hf/empagliflozin/prescribing-information/empagliflozin-jardiance-prescribing-information

Empagliflozin (Jardiance®) Prescribing Information
/ph/metabolic-hf/empagliflozin/experts-video/early-use-of-empagliflozin-jardiance-in-the-full-spectrum-of-hf

1:30
JREIHF||Early use of Empagliflozin (JARDIANCE) in the full spectrum of HF
/ph/metabolic-hf/empagliflozin/experts-video/empagliflozin-jardiance-improves-the-qol-of-hf-patients

1:58
JREIHF||Empagliflozin (JARDIANCE) improves the QoL of HF patients
/ph/metabolic-hf/empagliflozin/experts-video/empagliflozin-jardiance-is-safe-for-hf-patients-without-t2d

2:22
JREIHF||Empagliflozin (JARDIANCE) is safe for HF patients without T2D
/ph/metabolic-hf/empagliflozin/experts-video/clinical-implication-of-the-new-indication-of-empagliflozin-jardiance-in-the-full-spectrum-of-hf

1:11
JREIHF||Clinical implication of the new indication of Empagliflozin Jardiance in the full spectrum of HF
/ph/metabolic-hf/empagliflozin/experts-video/use-of-empagliflozin-jardiance-in-hf-patients-with-low-egfr

2:17
JREIHF||Use of Empagliflozin Jardiance in HF patients with Low eGFR
/ph/metabolic-hf/empagliflozin/experts-video/consistent-cv-benefit-of-empagliflozin-jardiance-in-the-full-spectrum-of-hf

1:56
JREIHF||Consistent CV benefit of Empagliflozin (JARDIANCE) in the full spectrum of HF
/ph/metabolic-hf/empagliflozin/experts-video/renal-efficacy-and-safety-of-empagliflozin-jardiance-in-the-full-spectrum-of-hf

2:06
JREIHF||Renal efficacy and safety of Empagliflozin (JARDIANCE) in the full spectrum of HF
/ph/metabolic-hf/empagliflozin/experts-video/metabolism-jardiance-emperor-preserved-expert-opinion-and-summary-video-15-7-22

3:14
Metabolism_Jardiance_EMPEROR-Preserved expert opinion and summary video_15-7-22
/ph/metabolic-hf/empagliflozin/experts-video/empagliflozin-jardiance-10mg-improves-quality-life-hfref

2:46
Empagliflozin (JARDIANCE) 10mg improves the quality of life in HFrEF
/ph/metabolic-hf/empagliflozin/experts-video/metabolismjardianceemperor-preserved-faq-expert-snippets-stefan-ankervideo15-7-22

16:08
Metabolism_Jardiance_EMPEROR-Preserved FAQ expert snippets - Stefan Anker_video_15-7-22
/ph/metabolic-hf/empagliflozin/experts-video/emperor-preserved-congress-presentation-video-stefan-ankervideo15-7-22

17:48
EMPEROR-Preserved congress presentation video – Stefan Anker_video_15-7-22
/ph/metabolic-hf/empagliflozin/experts-video/advantages-empagliflozin-jardiance-hfref

1:28
Advantages of Empagliflozin (JARDIANCE) in HFrEF
/ph/metabolic-hf/empagliflozin/experts-video/metabolismjardianceemperor-preserved-faq-expert-snippets-carolyn-lamvideo15-7-22

13:08
Metabolism_Jardiance_EMPEROR-Preserved FAQ expert snippets - Carolyn Lam_video_15-7-22
/ph/metabolic-hf/empagliflozin/experts-video/empagliflozin-jardiance-low-egfr-hfref-patients

0:54
Empagliflozin (JARDIANCE) in low eGFR HFrEF patients
/ph/metabolic-hf/empagliflozin/experts-video/how-empagliflozin-jardiance-10-mg-provide-cardio-renal-benefits-hfref

6:00
How Empagliflozin (JARDIANCE) 10 mg provide Cardio-Renal benefits in HFrEF
/ph/metabolic-hf/empagliflozin/experts-video/consistent-cv-benefits-hfref

3:28
Consistent CV benefits in HFrEF
/ph/metabolic-hf/empagliflozin/experts-video/empagliflozin-jardiance-is-simple-and-easy-to-use

1:38
Empagliflozin (JARDIANCE) is simple and easy to use
/ph/metabolic-hf/empagliflozin/experts-video/empagliflozin-jardiances-consistent-cv-and-renal-benefits-hfref

42:25
Empagliflozin (JARDIANCE)'s Consistent CV and Renal Benefits in HFrEF
/ph/metabolic-hf/empagliflozin/experts-video/jardiance-10mg-safe-heart-failure

1:32

Jardiance 10mg is Safe in Heart failure
/ph/metabolic-hf/empagliflozin/experts-video/how-safe-empagliflozin-jardiance-hfref

1:32

How safe is Empagliflozin (JARDIANCE) in HFrEF

Cardiovascular

  • Dabigatran etexilate
  • Telmisartan
/ph/cardiovascular/dabigatran-etexilate/efficacy/patient-story-1

8:28
Patient Story 1
/ph/cardiovascular/dabigatran-etexilate/efficacy/efficacy-safety-pradaxa-110mg

Efficacy Safety Pradaxa 110mg
/ph/cardiovascular/dabigatran-etexilate/safety/safety-both-doses

Safety Both Doses
/ph/cardiovascular/dabigatran-etexilate/safety/patient-story-2

5:47
Patient Story 2
/ph/cardiovascular/dabigatran-etexilate/efficacy/efficacy-pradaxa-150mg

Efficacy Pradaxa 150mg
/ph/cardiovascular/dabigatran-etexilate/reversibility/reversibility-campaign-video

1:47

Reversibility Campaign Video
/ph/cardiovascular/dabigatran-etexilate/safety/gloria-a-pase-3-results

1:45
GLORIA-AF Phase 3 Results
/ph/cardiovascular/dabigatran-etexilate/safety/lower-risk-major-bleeding-dabigatran-vs-rivaroxaban-real-world-analysis

Lower risk of major bleeding with Dabigatran vs Rivaroxaban from a real-world analysis
/ph/cardiovascular/dabigatran-etexilate/prescribing-information/idarucizumab-praxbind-prescribing

Idarucizumab (Praxbind®) Prescribing Information
/ph/cardiovascular/dabigatran-etexilate/safety/re-ly-trial-landmark-study-cardiology

2:33
The RE-LY Trial: A Landmark Study in Cardiology
/ph/cardiovascular/dabigatran-etexilate/safety/re-ly-asia-asian-vs-non-asian-dr-masatsugu-hori

14:13

RE-LY Asia: Asian vs Non-Asian by Dr. Masatsugu Hori
/ph/cardiovascular/dabigatran-etexilate/safety/noac-safety-clinical-practice-evidence-real-world

6:52
NOAC Safety in Clinical Practice: Evidence from the Real World
/ph/cardiovascular/dabigatran-etexilate/dosage-administration/idarucizumab-praxbind-administration

2:26
Idarucizumab (Praxbind®) Administration Video
/ph/cardiovascular/dabigatran-etexilate/prescribing-information/dabigatran-etexilate-prescribing

Dabigatran etexilate (Pradaxa®) Prescribing information
/ph/cardiovascular/dabigatran-etexilate/mode-action

02:20
Mode of Action of Idarucizumab (Praxbind®)
/ph/cardiovascular/telmisartan/24-hour-bp-control/mild-moderate-hypertension-thomas-unger-telmisartan

4:23
Mild to Moderate Hypertension - Thomas Unger - Telmisartan
/ph/cardiovascular/telmisartan/cardiovascular-protection/high-risk-hpn-patients-thomas-unger-telmisartan

3:59
High Risk HPN Patients - Thomas Unger - Telmisartan
/ph/cardiovascular/telmisartan/cardiovascular-protection/role-twynsta-thomas-unger-telmisartan

5:37
Role of Twynsta - Thomas Unger - Telmisartan
/ph/cardiovascular/telmisartan/cardiovascular-protection/hpn-t2d-thomas-unger-telmisartan

5:37
HPN with T2D - Thomas Unger - Telmisartan
/ph/cardiovascular/telmisartan/renal-benefits/hpn-ckd-thomas-unger-telmisartan

3:27
HPN with CKD - Thomas Unger - Telmisartan
/ph/cardiovascular/telmisartan/cardiovascular-protection/boehringer-ingelheims-telmisartan-only-arb-that-is-indicated-reduce-both-cv

3:57
Boehringer Ingelheim’s Telmisartan is the ONLY ARB that is INDICATED* to reduce both CV morbidity and mortality for high-risk patients
/ph/cardiovascular/telmisartan/24-hour-bp-control/start-with-boehringer-ingelheims-telmisartan-inmild-to-moderate-hypertensive-patients

4:16
Start with Boehringer Ingelheim’s Telmisartan in mild to moderate hypertensive patients
/ph/cardiovascular/telmisartan/renal-benefits/boehringer-ingelheims-telmisartan-provides-renal-benefits-to-high-risk-hypertensive-patients

3:37
Boehringer Ingelheim’s Telmisartan provides renal benefits to high-risk* hypertensive patients
/ph/cardiovascular/telmisartan/renal-benefits/boehringer-ingelheims-telmisartan-provides-cv-and-renal-benefits-to-t2d-hypertensive-patients-with-diabetic-nephropathy

2:58
Boehringer Ingelheim's Telmisartan provides CV and renal benefits to T2D hypertensive patients with diabetic nephropathy
/ph/cardiovascular/telmisartan/24-hour-bp-contro/the-multiple-benefits-of-telmisartan-bpcs-are-aligned-with-updated-standards-of-care-from-international-guidelines-1

7:08
The multiple benefits of Telmisartan-based SPCs are aligned with updated standards of care from international guidelines1
/ph/cardiovascular/telmisartan/24-hour-bp-control/start-early-telmisartan-mild-moderate-hypertensive-patients

1:32
Start Early with Telmisartan in Mild-to-moderate Hypertensive Patients
/ph/cardiovascular/telmisartan/cv-protection/telmisartan-only-arb-proven-and-indicated-provide-cv-protection-high-risk-patients

00:00
Telmisartan is the ONLY ARB proven and indicated to provide CV protection for high risk patients
/ph/cardiovascular/telmisartan/renal-benefits/telmisartan-superior-losartan-reducing-proteinuria-hypertensive-patients-diabetic

00:00
Telmisartan is superior to losartan in reducing proteinuria in hypertensive patients with diabetic nephropathy
/ph/cardiovascular/telmisartan/24-hour-bp-control/telmisartan-as-initial-dose-for-hypertension

00:00
Telmisartan as initial dose for hypertension
/ph/cardiovascular/telmisartan/24-hour-bp-control/telmisartan-is-more-effective-than-ramipril-throughout-the-24-h-period

Telmisartan is more effective than ramipril throughout the 24-h period and during the early morning BP surge
/ph/cardiovascular/micardis/cost-effectivess-price-comparison-micardis-twynsta

2:19
Cost Effectiveness – Price Comparison of Telmisartan (Micardis®) & Telmisartan + Amlodipine besilate (Twynsta®)
/ph/cardiovascular/telmisartan/24-hour-bp-control/only-telmisartan-has-unique-delta-lock-structure-which-contributes-its-prolonged

1:49
Only Telmisartan has the unique Delta Lock structure which contributes to its prolonged duration of BP lowering action
/ph/cardiovascular/telmisartan/renal-benefits/boehringer-ingelheims-telmisartan-reduces-proteinuria-hypertensive-patients

1:38
Boehringer Ingelheim’s Telmisartan reduces proteinuria in hypertensive patients with diabetic nephropathy
/ph/cardiovascular/telmisartan/cardiovascular-protection/boehringer-ingelheims-telmisartan-only-arb-indicated-reduce-both-cv

1:42

Boehringer Ingelheim’s Telmisartan is the ONLY ARB INDICATED* to reduce both CV morbidity and mortality for high-risk patients
/ph/cardiovascular/telmisartan/24-hour-bp-control/vs-other-arbs-boehringer-ingelheims-telmisartan-has-highest-plasma-half-life

1.32
Vs. other ARBs, Boehringer Ingelheim’s Telmisartan has the highest plasma half-life leading to 24-hour BP Control
/ph/cardiovascular/telmisartan/quality-and-legacy/boehringer-ingelheims-telmisartan-backed-quality-legacy-clinical-evidence

3:49

Boehringer Ingelheim’s Telmisartan: Backed up by Quality, Legacy, Clinical Evidence
/ph/cardiovascular/telmisartan/renal-benefits/boehringer-ingelheims-telmisartan-preserves-renal-function-hypertensive-patients

1:38

Boehringer Ingelheim’s Telmisartan preserves renal function in hypertensive patients with type 2 diabetic nephropathy

Metabolic

  • Empagliflozin
  • Linagliptin
  • Empagliflozin + Linagliptin
/ph/metabolic/empagliflozin/experts-video/early-initiation-improve-quality-life

1:11
JRDHF||Early initiation to improve quality of life
/ph/metabolic/empagliflozin/experts-video/how-effective-empagliflozin-or-without-arni

1:11
JRDHF||How effective is Empagliflozin with or without ARNI?
/ph/metabolic/empagliflozin/experts-video/how-early-can-you-give-empagliflozin

1:35
JRDHF||How early can you give Empagliflozin?
/ph/metabolic/empagliflozin/experts-video/how-confident-are-you-start-empagliflozin-non-t2d-hf-patients

1:01
JRDHF||How confident are you to start Empagliflozin to non-T2D HF patients?
/ph/metabolic/empagliflozin/experts-video/renal-efficacy-and-safety-empagliflozin-hf

1:09
JRDHF||Renal efficacy and safety of Empagliflozin in HF
/ph/metabolic/empagliflozin/experts-video/what-clinical-implication-empagliflozin-hf

0:54
JRDHF||What is the clinical implication of Empagliflozin in HF
/ph/metabolic/empagliflozin/experts-video/empagliflozin-jardiance-improved-quality-life-hf-patients

1:58
Empagliflozin (JARDIANCE) improved the quality of life of HF patients
/ph/metabolic/empagliflozin/experts-video/empagliflozin-jardiance-provides-robust-renal-benefits-full-spectrum-hf

2:06
Empagliflozin (JARDIANCE) provides robust renal benefits in the full spectrum of HF
/ph/metabolic/empagliflozin/experts-video/empagliflozin-jardiance-provides-consistent-cv-benefits-across-lvef

1:56
Empagliflozin (JARDIANCE) provides consistent CV benefits across LVEF
/ph/metabolic/empagliflozin/experts-video/empagliflozin-jardiance-safe-full-spectrum-hf-or-without-t2d

2:22
Empagliflozin (JARDIANCE) is safe in the full spectrum of HF with or without T2D
/ph/metabolic/empagliflozin/experts-video/what-clinical-implication-empagliflozin-jardiance-full-spectrum-hf

1:11
What is the clinical implication of Empagliflozin (JARDIANCE) in the full spectrum of HF?
/ph/metabolic/empagliflozin/experts-video/empagliflozin-jardiance-early-hf-management

1:30
Empagliflozin (JARDIANCE) Early in HF management
/ph/metabolic/empagliflozin/experts-video/can-you-give-empagliflozin-hf-patients-low-egfr

2:17
Can you give Empagliflozin in HF patients with low eGFR?
/ph/metabolic/empagliflozin/jardiance-hf/empagliflozin-jardiances-consistent-cv-and-renal-benefits-hfref

42:25
Empagliflozin (JARDIANCE)'s Consistent CV and Renal Benefits in HFrEF
/ph/metabolic/empagliflozin/experts-video/metabolism-jardiance-emperor-preserved-expert-opinion-and-summary-video-15-7-22

3:14
Metabolism_Jardiance_EMPEROR-Preserved expert opinion and summary video_15-7-22
/ph/metabolic/empagliflozin/jardiance-hf/empagliflozin-jardiance-10mg-improves-quality-life-hfref

2:46
Empagliflozin (JARDIANCE) 10mg improves the quality of life in HFrEF
/ph/metabolic/empagliflozin/experts-video/metabolismjardianceemperor-preserved-faq-expert-snippets-stefan-ankervideo15-7-22

16:08
Metabolism_Jardiance_EMPEROR-Preserved FAQ expert snippets - Stefan Anker_video_15-7-22
/ph/metabolic/empagliflozin/experts-video/emperor-preserved-congress-presentation-video-stefan-ankervideo15-7-22

17:48
EMPEROR-Preserved congress presentation video – Stefan Anker_video_15-7-22
/ph/metabolic/empagliflozin/jardiance-hf/advantages-empagliflozin-jardiance-hfref

1:28
Advantages of Empagliflozin (JARDIANCE) in HFrEF
/ph/metabolic/empagliflozin/experts-video/metabolismjardianceemperor-preserved-faq-expert-snippets-carolyn-lamvideo15-7-22

13:08
Metabolism_Jardiance_EMPEROR-Preserved FAQ expert snippets - Carolyn Lam_video_15-7-22
/ph/metabolic/empagliflozin/jardiance-hf/how-empagliflozin-jardiance-10-mg-provide-cardio-renal-benefits-hfref

6:00
How Empagliflozin (JARDIANCE) 10 mg provide Cardio-Renal benefits in HFrEF
/ph/metabolic/empagliflozin/jardiance-hf/empagliflozin-jardiance-low-egfr-hfref-patients

0:54
Empagliflozin (JARDIANCE) in low eGFR HFrEF patients
/ph/metabolic/empagliflozin/efficacy/whats-new-emprise-data

What's New in EMPRISE data?
/ph/metabolic/empagliflozin/experts-video/consistent-cv-benefits-hfref

3:28
Consistent CV benefits in HFrEF
/ph/metabolic/empagliflozin/cv-risk-protection/empagliflozin-more-just-t2d-drug

1:03
Empagliflozin is more than just a T2D drug
/ph/metabolic/empagliflozin/efficacy/empagliflozin-safety-tolerability-profile

1:43
Empagliflozin safety & tolerability profile
/ph/metabolic/empagliflozin/empa-reg-outcome-trial/effecvts-empagliflozin-heart-kidneys

1:03
Effecvts of Empagliflozin in the heart & kidneys
/ph/metabolic/empagliflozin/experts-video/empagliflozin-jardiance-is-simple-and-easy-to-use

1:38
Empagliflozin (JARDIANCE) is simple and easy to use
/ph/metabolic/empagliflozin/jardiance-10mg-safe-heart-failure

1:32

Jardiance 10mg is Safe in Heart failure
/ph/metabolic/empagliflozin/experts-video/how-safe-empagliflozin-jardiance-hfref

1:32

How safe is Empagliflozin (JARDIANCE) in HFrEF
/ph/metabolic/empagliflozin/cv-risk-protection/unique-cv-death-reduction-empagliflozin

1:31
Unique CV death reduction of Empagliflozin
/ph/metabolic/empagliflozin/cv-risk-protection/empagliflozin-beyond-glucose-lowering-prof-sanjay-kaul

1:42
Empagliflozin beyond glucose lowering by Prof. Sanjay Kaul
/ph/metabolic/empagliflozin/efficacy/holistic-crm-management-empaglifozin-prof-alice-cheng

1:42
Holistic CRM management with Empaglifozin by Prof. Sanjay Kaul
/ph/metabolic/empagliflozin/efficacy/empagliflozins-safety-tolerability-profile-vs-dpp4i-prof-alice-cheng

2:36
Empagliflozin's safety & tolerability profile vs DPP4i by Prof. Alice Cheng
/ph/metabolic/time-meets-power

1:19
Embark now gain more video
/ph/metabolic/empagliflozin/when-time-meets-power/gift-time-video

0:48
Gift of Time Video
/ph/metabolic/empagliflozin/when-time-meets-power/time-meets-power-all-one-one-all

1:15

Time meets power All for One, One for All
/ph/metabolic/empagliflozin/when-time-meets-power/time-meets-power-take-lead-act-now

3:54

Time meets power Take the lead, Act now
/ph/metabolic/empagliflozin/cv-risk-protection/empagliflozins-unique-38-cv-death-risk-reduction

1:16
Empagliflozin’s unique 38% CV death Risk reduction
/ph/metabolic/empagliflozin/when-time-meets-power/time-meets-power-might-3-one-experts-video

3:18
Time meets power Might of 3 in one expert’s video
/ph/metabolic/empagliflozin/cv-risk-protection/emprise-rwe-updates-ada-2020

EMPRISE RWE updates from ADA 2020
/ph/metabolic/empagliflozin/efficacy/unlocking-crm-link-t2d

59:54
Unlocking The CRM link in T2D
/ph/metabolic/empagliflozin/guidelines/phmore-80-guidelines-worldwide-endorse-empagliflozin

More than 80 guidelines worldwide endorse empagliflozin (Jardiance)
/ph/metabolic/empagliflozin/efficacy/prof-carvalho-discussing-cv-death-reduction-empa-reg

1:16
Prof. Carvalho discussing CV Death reduction in EMPA-REG
/ph/metabolic/empagliflozin/efficacy/defining-high-risk-and-very-high-risk-patients-t2d

1:41
Defining HIGH risk and VERY HIGH risk patients with T2D
/ph/metabolic/empagliflozin/efficacy/reduce-risk-cv-death-t2d-patients-high-cv-risk

1:40
Reduce the risk of CV death for T2D patients with high CV risk
/ph/metabolic/empagliflozin/efficacy/passive-cardio-cv-safe-not-enoughee-prof-davies

1:11
Passive Cardio CV Safe is not Enough by Prof Davies
/ph/metabolic/empagliflozin/efficacy/ee-video-prof-melanie-davies-defining-high-very-high-risk

1:34
EE Video Prof. Melanie Davies defining High & Very High risk patients
/ph/metabolic/empagliflozin/empa-reg-outcome-trial/empagliflozin-cv-indication-wave-change-across

Empagliflozin CV indication : A wave of change across the world
/ph/metabolic/empagliflozin/empa-reg-outcome-trial/empa-reg-outcome-breakthrough-trial-type-2

EMPA-REG OUTCOME: A Breakthrough trial in Type 2 Diabetes
/ph/metabolic/empagliflozin/efficacy/empagliflozin-allows-you-protect-patients

01:46
Empagliflozin allows you to protect patients from CV risks/death
/ph/metabolic/empagliflozin/cv-risk-protection/seeing-through-cv-risk-continuum

53:54
Seeing through the CV Risk Continuum: How Empagliflozin benefits patients across the spectrum
/ph/metabolic/empagliflozin/guidelines/t2d-cvd-risk-equivalent

T2D is a CVD risk equivalent
/ph/metabolic/empagliflozin/guidelines/definition-very-high-risk-patients-esc-2019-guidelines

05:12
Definition of very high risk patients as per ESC 2019 Guidelines
/ph/metabolic/empagliflozin/experts-interview/empagliflozin-provides-hba1c-reduction-vs-su-dr-alice-cheng

01:49
Empagliflozin (Jardiance®) offers reduces CV death, all-cause mortality, blood pressure and weight vs SU and DPP4i
/ph/metabolic/empagliflozin/prescribing-information/empagliflozin-metformin-hci-jardiance-duo

Empagliflozin Metformin HCI (Jardiance Duo®) Prescribing Information
/ph/metabolic/empagliflozin/prescribing-information/empagliflozin-jardiance-prescribing-information

Empagliflozin (Jardiance®) Prescribing Information
/ph/metabolic/empagliflozin/empa-reg-outcome-trial/empa-reg-outcome-study-result

EMPA-REG Outcome study result
/ph/metabolic/linagliptin/elearning/with-linagliptin-one-dose-fits-all

2:48

NDPP4||With Linagliptin, One Dose Fits All
/ph/metabolic/linagliptin/elearning/are-all-dpp4i-equal-in-terms-of-evidence

5:24

NDPP4||Are all DPP4i equal in terms of evidence?
/ph/metabolic/linagliptin/elearning/prof-jacob-evidence-based-medicine

13:20
NDPP4||Prof Jacob on Evidence-based Medicine
/ph/metabolic/linagliptin/safety/expert-video-series-carolina-only-cvot-active-comparator-glimepiride

4:47
NDPP4||Expert Video Series: CAROLINA - the only CVOT with an active comparator, glimepiride
/ph/metabolic/linagliptin/safety/expert-video-series-what-makes-carmelina-stand-out-vs-other-dpp4i-cvots

5:23
NDPP4||Expert Video Series: What makes CARMELINA stand out vs other DPP4i CVOTs
/ph/metabolic/linagliptin/dosing-convenience/expert-video-1-not-all-dpp4i-are-same-dosing-simplicity

3:29
NDPP4||Expert Video #1. Not All DPP4i are the same-dosing & simplicity
/ph/metabolic/linagliptin/simplicity/not-all-dpp4i-are-same

2:35
NDPP4||Not All DPP4i are the Same
/ph/metabolic/linagliptin/safety/real-world-evidencefragment

NDPP4||ASK-TRA-T2D-RED-2||Real-world evidence_Fragment
/ph/metabolic/linagliptin/safety/treatment-linagliptin-trajenta-top-soc-resulted-lesser-cv-and-renal-events

Treatment with Linagliptin (TRAJENTA®) on top of SOC resulted to lesser CV and renal events
/ph/metabolic/linagliptin/prescribing-information/linagliptinmetformin-hcl-trajenta-duo-now-bottles

Linagliptin+Metformin HCl (TRAJENTA DUO®) now in BOTTLES!
/ph/metabolic/linagliptin/dosing-convenience/not-all-dpp4i-are-the-same-in-dosing

Not all DPP4i are the Same in Dosing
/ph/metabolic/linagliptin/safety/ask-expert-prof-obrien-renal-safety

1:41
Ask the Expert: Prof. O'Brien on Renal Safety
/ph/metabolic/linagliptin/safety/ask-expert-prof-obrien-cv-safety

1:54
Ask the Expert: Prof. O'Brien on CV Safety
/ph/metabolic/linagliptin/efficacy/ask-expert-prof-obrien-efficacy

1:18
Ask the Expert: Prof. O'Brien on Efficacy
/ph/metabolic/linagliptin/dosing-convenience/ask-expert-prof-obrien-dosing-convenience

1:14
Ask the Expert: Prof. O'Brien on Dosing Convenience
/ph/metabolic/linagliptin/simplicity/ask-expert-prof-obrien-broad-range-patients

2:12
Ask the Expert: Prof O'Brien on Broad Range of Patients
/ph/metabolic/linagliptin/cv-renal-safety/trajenta-alice-cheng-combined-interview-video

5:26
Trajenta - Alice Cheng - Combined - Interview Video
/ph/metabolic/linagliptin/cv-renal-safety/dr-mike-cummings-10-carmelina®-only-study-included-kidney-related-secondary-end

1:08

Dr. Mike Cummings 10 - CARMELINA® is the only study that included a kidney-related secondary end point. The study showed no difference in outcome between Trajenta® and placebo
/ph/metabolic/linagliptin/efficacy/dr-mike-cummings-3-trajenta-can-be-used-broad-range-t2d-patients-independent-kidney

0:47
Dr. Mike Cummings 3 - Trajenta® can be used in a broad range of T2D patients, independent of kidney function
/ph/metabolic/linagliptin/cv-renal-safety/dr-mike-cummings-9-carmelina-reinforces-safety-profile-linagliptin-broad-range

0:50

Dr. Mike Cummings 9 - CARMELINA® reinforces the safety profile of linagliptin in a broad range of patients and supports the simplicity of use
/ph/metabolic/linagliptin/cv-renal-safety/dr-mike-cummings-8-carmelina-linagliptin-established-cardiovascular-and-kidney

0:47

Dr. Mike Cummings 8 - With CARMELINA®, linagliptin established the cardiovascular and kidney safety profile along with no risk of hospitalisation for heart failure
/ph/metabolic/linagliptin/cv-renal-safety/dr-mike-cummings-7-carmelina-unique-it-includes-patients-high-cardiovascular-risk

0:54
Dr. Mike Cummings 7 - CARMELINA® is unique as it includes patients high cardiovascular risk and, in many instances, with impaired renal function
/ph/metabolic/linagliptin/efficacy/dr-mike-cummings-6-55-year-old-male-hba1c-8-metformin-normal-renal-function-trajenta

1:14

Dr. Mike Cummings 6 - 55-year-old male; HbA1c 8%; on metformin; normal renal function; Trajenta® is an appropriate option when a DPP4i is needed
/ph/metabolic/linagliptin/efficacy/dr-mike-cummings-5-trajenta-can-be-used-across-heterogenous-patient-population-when-dpp4i

0:29

Dr. Mike Cummings 5 - Trajenta® can be used across a heterogenous patient population when a DPP4i is needed
/ph/metabolic/linagliptin/efficacy/dr-mike-cummings-4-trajenta-can-be-used-broad-range-patients-whenever-dpp4i-needed

0:37

Dr. Mike Cummings 4 - Trajenta® can be used in a broad range of patients whenever a DPP4i is needed
/ph/metabolic/linagliptin/simplicity/dr-mike-cummings-2-simplicity-trajenta-within-dpp4i-class

1:10

Dr. Mike Cummings 2 - Simplicity of Trajenta® within the DPP4i class
/ph/metabolic/linagliptin/efficacy/dr-mike-cummings-1-trajenta-consistently-lowers-hba1c-line-other-dpp4i

0:35

Dr. Mike Cummings 1 - Trajenta® consistently lowers HbA1c in line with other DPP4i
/ph/metabolic/linagliptin/dosing-convenience/linagliptin-trajenta-true-convenience-broad-range-patients

00:00
Linagliptin (Trajenta): True convenience for a broad range of patients
/ph/metabolic/linagliptin/simplicity/limited-kidney-video-prof-roger-chen

6:39
Limited to kidney video by Prof. Roger Chen
/ph/metabolic/linagliptin/simplicity/limited-kidney-video-dr-peter-lin

2:17
Limited to kidney video by Dr. Peter Lin
/ph/metabolic/linagliptin/cv-renal-safety/cv-and-kidney-safety-linagliptin-trajenta-asian-patients

CV and kidney safety of Linagliptin (Trajenta®) in asian patients
/ph/metabolic/linagliptin/efficacy/efficacy-linagliptin-trajenta-vs-other-dpp4i

Efficacy of Linagliptin (Trajenta®) vs other DPP4i
/ph/metabolic/linagliptin/simplicity/linagliptin-trajenta-simplicity-and-convenience

2:00
Linagliptin (Trajenta®) simplicity and convenience
/ph/metabolic/linagliptin/cv-renal-safety/carmelina-confirms-long-term-cv-and-renal-safety-linagliptin-trajenta-cv-and-renal

1:49
CARMELINA: Confirms long-term CV and renal safety of Linagliptin (Trajenta®) in CV and renal risk T2D patients
/ph/metabolic/linagliptin/cv-renal-safety/carmelina-reinforces-simplicity-linagliptin-trajenta-broad-range-t2d-patients

2:50
CARMELINA: Reinforces simplicity of Linagliptin (Trajenta®) in a broad range of T2D patients
/ph/metabolic/linagliptin/simplicity/10-years-of-simplicity-t2d-management

10 Years of Simplicity in T2D Management
/ph/metabolic/linagliptin/simplicity/10-years-simplicity-t2d-management

10 Years of Simplicity in T2D Management
/ph/metabolic/linagliptin/simplicity/10-years-simplicity-linagliptin

1:57
10 Years of Simplicity with Linagliptin
/ph/metabolic/linagliptin/cv-renal-safety/carmelina

CARMELINA
/ph/metabolic/linagliptin/cv-renal-safety/linagliptin-safe-across-t2d-patient-age-groups-including-elderly

Linagliptin is safe across T2D patient age groups, including the Elderly
/ph/metabolic/linagliptin/simplicity/relevance-linagliptin-2021

6:34
Relevance of Linagliptin in 2021
/ph/metabolic/linagliptin/efficacy/efficacy

Efficacy
/ph/metabolic/linagliptin/simplicity/simplicity-trajenta

39:49
Simplicity of Trajenta
/ph/metabolic/linagliptin/efficacy/linagliptin-efficacy-data

Linagliptin Efficacy Data
/ph/metabolic/linagliptin/simplicity/simplicity-believer-video-ted-wu

4:08
Simplicity Believer Video - Ted Wu
/ph/metabolic/linagliptin/simplicity/limited-kidney-video-roger-chen

6:35
Limited to Kidney Video - Roger Chen
/ph/metabolic/linagliptin/simplicity/trajenta-recorded-webinar-henrik-groop

59:50
Trajenta Recorded Webinar - Per Henrik Groop
/ph/metabolic/linagliptin/efficacy/linagliptin-efficacy-vs-other-dpp4i-fue

Linagliptin Efficacy vs Other DPP4i FUE
/ph/metabolic/linagliptin/cv-renal-safety/trajenta-cvot-infographic

Trajenta CVOT infographic
/ph/metabolic/linagliptin/cv-renal-safety/carmelina-cvot-video

1:50
Carmelina CVOT Video
/ph/metabolic/linagliptin/efficacy/simplicity

2:17
Simplicity
/ph/metabolic/linagliptin/cv-renal-safety/ph-trajenta-carolina-video-102020

2:25
PH Trajenta CAROLINA video 102020
/ph/metabolic/linagliptin/simplicity/pcdr-esteban-jodar-06-trajenta-ph-video

0:48
With CARMELINA®, linagliptin demonstrated a long-term cardiovascular safety profile in patients with T2D and showed no increase in risk of hospitalisation for heart failure
/ph/metabolic/linagliptin/simplicity/dr-esteban-jodar-07-carmelina-simplicity-trajenta-reinforced

0:31
Dr. Esteban Jodar 07 - With CARMELINA®, the simplicity of Trajenta® is reinforced by the reinforced safety profile, established efficacy and the convenience of one dose once daily
/ph/metabolic/linagliptin/cv-renal-safety/4q-trajenta-opd-video-sb-mark-cooper

2:24
4Q Trajenta OPD Video-SB-Mark Cooper
/ph/metabolic/linagliptin/cv-renal-safety/cv-and-kidney-safety-linagliptin-ina-asians-adc

CV and Kidney Safety of Linagliptin ina Asians ADC
/ph/metabolic/linagliptin/efficacy/linagliptin-efficacy-vs-other-dpp4i-adc

Linagliptin Efficacy vs Other DPP4i ADC
/ph/metabolic/linagliptin/simplicity/linagliptin-simplicity-and-convenience-adc

2:00
Linagliptin Simplicity and Convenience ADC
/ph/metabolic/linagliptin/cv-renal-safety/linagliptin-trajenta-simplicity-broad-range-patients

Linagliptin (TRAJENTA®): Simplicity in a broad range of patients
/ph/metabolic/linagliptin/cv-renal-safety/carolina-asian-subanalysis

Carolina Asian Subanalysis
/ph/metabolic/linagliptin/cv-renal-safety/carmelina-asian-subanalysis

CARMELINA Asian Subanalysis
/ph/metabolic/linagliptin/efficacy/meta-analysis-sglt2-inhibitors

01:50
Meta-analysis of SGLT2 inhibitors
/ph/metabolic/linagliptin/cv-renal-safety/linagliptin-cvot-program-provides-evidence

01:50
Linagliptin's CVOT program provides evidence of its safety for a broad range of patients
/ph/metabolic/linagliptin/simplicity/what-are-key-results-carmelina-carolina

2:19
What are the key results of CARMELINA/CAROLINA and why is it unique vs other DPP4i CVOTs?
/ph/metabolic/linagliptin/cv-renal-safety/what-makes-carmelina-trial-unique

22:54
What makes CARMELINA Trial unique versus other DPP4i CVOTS? by Dr. Alice Cheng
/ph/metabolic/linagliptin/cv-renal-safety/linagliptin-trajenta-demonstrated-good-safety-profile

Linagliptin (Trajenta®): Demonstrated good safety profile in patients across the type 2 diabetes continuum based on its CVOTs
/ph/metabolic/linagliptin/cv-renal-safety/linagliptin-trajenta-carolina

2:25
Linagliptin (Trajenta®) in CAROLINA
/ph/metabolic/linagliptin/cv-renal-safety/carmelina-cv-and-renal-safety-profile-linagliptin-trajenta

07:35
CARMELINA: CV and renal safety profile of Linagliptin (Trajenta®)
/ph/metabolic/linagliptin/cv-renal-safety/linagliptin-demonstrates-efficacy-safety

Linagliptin demonstrates efficacy & safety in T2D, including those with high CV & renal risk
/ph/metabolic/linagliptin/cv-renal-safety/carmelina-trial-reinforces-simplicity

02:51
CARMELINA Trial reinforces simplicity of use of Linagliptin (Trajenta®) in a broad range of T2D patients
/ph/metabolic/linagliptin/cv-renal-safety/linagliptin-trajenta-combines-efficacy

02:17
Linagliptin (Trajenta®) combines efficacy and good safety profile across a broad range of T2D patients
/ph/metabolic/linagliptin/cv-renal-safety/carmelina-trial-summary

04:32
CARMELINA Trial Summary
/ph/metabolic/linagliptin/efficacy/patient-case-2-achieving-optimal-management

21:37
Patient case 2: Achieving optimal management in an elderly patient with declining renal function
/ph/metabolic/linagliptin/efficacy/patient-case-1-achieving-optimal-management

23:30
Patient case 1: Achieving optimal management while considering poor treatment compliance and renal function decline
/ph/metabolic/linagliptin/prescribing-information/linagliptin-metformin-hcl-trajenta-duo-prescribing

Linagliptin Metformin HCl (Trajenta Duo®) Prescribing Information
/ph/metabolic/linagliptin/prescribing-information/linagliptin-trajenta-prescribing-information

Linagliptin (Trajenta®) Prescribing Information
/ph/metabolic/empagliflozin-linagliptin/efficacy/consistent-renal-benefit-of-individual-components

1:51
MPPGLY||Consistent renal benefit of individual components
/ph/metabolic/empagliflozin-linagliptin/efficacy/glyxambi-is-beneficial-in-t2d-patients-with-no-established-cv-disease

1:20
MPPGLY||Glyxambi is beneficial in T2D patients with no Established CV Disease
/ph/metabolic/empagliflozin-linagliptin/cv-and-renal-safety/linagliptin-trajenta-demonstrates-cv-and-kidney-safety-across-various-age

Linagliptin (Trajenta) is is proven safe across different age groups
/ph/metabolic/empagliflozin-linagliptin/safety/non-adherence-medication-among-t2d-patients

0:51
Non-adherence in medication among T2D Patients
/ph/metabolic/empagliflozin-linagliptin/efficacy/overcoming-challenges-glycemic-control

2:20
Overcoming challenges in glycemic control
/ph/metabolic/empagliflozin-linagliptin/safety/non-adherence-not-just-when-why

4:56
Non adherence: Not just WHEN but WHY
/ph/metabolic/empagliflozin-linagliptin/safety/be-control-across-crm-outcomes-t2d

2:54
Be in control across CRM Outcomes in T2D
/ph/metabolic/empagliflozin-linagliptin/safety/prof-ralph-de-fronzos-expert-opinion-why-glyxambi-good-combination-t2d

4:56
Prof. Ralph De Fronzo’s expert opinion why Glyxambi is a good combination in T2D
/ph/metabolic/empagliflozin-linagliptin/safety/prof-ralph-de-fronzos-expert-opinion-safety-profile-glyxambi

4:49
Prof. Ralph De Fronzo’s expert opinion on the safety profile of Glyxambi
/ph/metabolic/empagliflozin-linagliptin/efficacy/glyxambi-microsite-demo-video

3:35
Glyxambi Microsite Demo Video
/ph/metabolic/empagliflozin-linagliptin/efficacy/recorded-webinar-ralph-de-fronzo

1:07:52
Recorded webinar of Ralph De Fronzo
/ph/metabolic/empagliflozin-linagliptin/efficacy/efficacy

Efficacy
/ph/metabolic/empagliflozin-linagliptin/efficacy/glyxambi-advantage-vs-other-fdc

33:25
Advantage of Glyxambi over other FDC
/ph/metabolic/empagliflozin-linagliptin/safety/cardiovascular-renal-safety

Cardiovascular & Renal Safety
/ph/metabolic/empagliflozin-linagliptin/efficacy/2020-american-association-clinical-endocrinology

2020 American Association of Clinical Endocrinology Guidelines
/ph/metabolic/empagliflozin-linagliptin/efficacy/multiple-benefits-one-small-pill

Multiple Benefits in one small pill
/content/external-expert-video-glyxambis-unique-advantages

3:16
External Expert video on Glyxambi's unique advantages
/content/external-expert-video-early-intensive-treatment

2:47

External Expert video on Early Intensive Treatment
/ph/metabolic/empagliflozin-linagliptin/efficacy/professor-javier-ampudia-webinar-expanding

58:52
Professor Javier Ampudia Webinar “Expanding Treatment Options for Glycemic Reduction in Patients with T2DM: Role of Empagliflozin+Linagliptin Combination
/ph/metabolic/empagliflozin-linagliptin/efficacy/recorded-webinar-mark-cooper-last-july-1-2020

35:53
Recorded webinar of Mark Cooper last July 1, 2020
/ph/metabolic/empagliflozin-linagliptin/efficacy/early-glycemic-control-treating-t2d-patients

2:13
Early glycemic control in treating T2D patients
/ph/metabolic/empagliflozin-linagliptin/efficacy/single-powerful-combination-pill

2:51
A single powerful combination pill
/ph/metabolic/empagliflozin-linagliptin/mode-action/single-powerful-combination-pill

0:57
Prof. Cooper Complementary actions of SGLT2i+DPP4i
/ph/metabolic/empagliflozin-linagliptin/efficacy/slow-down-progression-t2d

1:21
Prof. Cooper Early Glycemic Control in T2D
/ph/metabolic/empagliflozin-linagliptin/efficacy/slow-intensification-and-treatment-will-lead-poor

00:00
Prof. Davies Wealth of Evidence in Early HbA1c control
/ph/metabolic/empagliflozin-linagliptin/efficacy/control-hba1c-early-phase

00:00
Prof. Carvalho Treat Early & Effectively
/ph/metabolic/empagliflozin-linagliptin/prescribing-information

Empagliflozin + Linagliptin (Glyxambi®) Prescribing Information

Respiratory

  • Tiotropium + olodaterol
/ph/respiratory/spiolto/respimat/video-how-to-use-respimat-bisaya-version

7:00

Video: How To Use Respimat (Bisaya Version)||ASK-SPL-COPD-RES-7
/ph/respiratory/spiolto/respimat/video-how-to-use-respimat-tagalog-version

7:00

Video: How To Use Respimat (Tagalog Version)||ASK-SPL-COPD-RES-7
/ph/respiratory/spiolto/respimat/video-how-to-use-respimat-english-version

7:00

Video: How To Use Respimat (English Version)||ASK-SPL-COPD-RES-7
/ph/respiratory/spiolto/expert-videos/inhaler-choice-what-important

35:50

Inhaler Choice: What is Important?
/ph/respiratory/spiolto/expert-videos/january-22-webinar-recording-prof-marc-miravitlles

38:15
January 22 Webinar Recording: Prof Marc Miravitlles
/ph/respiratory/spiolto/inhaleability/pc-ph-102782-inhaleability-video

1:32
PC-PH-102782 Inhaleability Video
/content/ph-spiolto-inhaleability-slider-design-video-chapter-2

2:53
PH Spiolto Inhaleability Slider Design Video - Chapter 2
/ph/respiratory/spiolto/quality-life/ph-spiolto-inhaleability-slider-design-video-chapter-1

1:56
PH Spiolto Inhaleability Slider Design Video - Chapter 1
/ph/respiratory/spiolto/efficacy/spiolto-respimat-inhaleability-infographic-092020

Tiotropium + olodaterol (Spiolto Respimat) Inhaleability Infographic 092020
/ph/respiratory/spiolto/expert-videos/phdrusmani-v32020

3:09
PH_Dr.Usmani V3_2020
/ph/respiratory/spiolto/expert-videos/phdrusmani-v42020

13:14
PH_Dr.Usmani V4_2020
/ph/respiratory/spiolto/expert-videos/dr-omar-usmaniwhat-factors-contribute-low-pifr

7:22
Dr. Omar Usmani_What factors contribute to low PIFR
/ph/respiratory/spiolto/expert-videos/dr-omar-usmaniwhat-are-important-considerations-while-selecting

14:45
Dr. Omar Usmani_What are the important considerations while selecting an inhaler for a COPD Patient
/ph/respiratory/spiolto/respimat/how-use-video-respimat

1:43
How to Use Video for Respimat Device
/ph/respiratory/spiolto/respimat/respimat-delivers-drug-deep-patient-lungs

02:53
Respimat® delivers drug deep into the patient's lungs without the need for forceful inhalation
/ph/respiratory/spiolto/respimat/52-copd-patients-have-suboptimal-peak-inspiratory-flow

01:55
52% of COPD patients have suboptimal Peak Inspiratory Flow (sPIF)
/ph/respiratory/spiolto/respimat/respimat-innovation-boehringer-ingelheim

01:59
Respimat® is an innovation from Boehringer Ingelheim and is the only Soft Mist Inhaler in the market
/ph/respiratory/spiolto/respimat/respimat-delivers-drug-actively-without-need-copd

03:29
Respimat® delivers drug actively without the need of COPD patients to forcefully inhale
/ph/metabolic/empagliflozin/guidelines/2019-esc-guidelines

2019 ESC Guidelines
/ph/respiratory/spiolto/prescribing-information

Tiotropium + olodaterol (Spiolto® Respimat®) Prescribing Information

Oncology

  • Afatinib
/ph/oncology/giotrif/sequencing/defining-optimal-tki-sequencing-patients-egfr-disease

35:10
Defining Optimal TKI Sequencing in EGFR M+ NSCLC: GioTag RWD Lecture by Professor Vera S. Hirsh, MD
/ph/oncology/giotrif/safety/realgido-real-world-study

RealGiDo - Real-world study on dose adjustment
/ph/oncology/giotrif-giotrif/giotrif-safety/realgido-real-world-data-tolerability-guided-dose-adjustment

21:05
Dose adjustment of Afatinib (Giotrif®): RealGiDo RWD Lecture by Professor Vera S. Hirsh, MD
/ph/oncology/giotrif/sequencing/giotag-real-world-study

GioTag: Real-world study on Afatinib (Giotrif®) followed by osimertinib in EGFR m+ NSCLC patients
/ph/oncology/giotrif/sequencing/optimising-outcomes

01:24
Optimising outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
/ph/oncology/giotrif/prescribing-information

Afatinib (Giotrif®) Prescribing Information